ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRY ARS PHARMACEUTICALS INC

Post-Market Trading 11-26 17:58:57 EST

14.37

+0.66

+4.81%

盘后14.75

+0.38+2.64%

16:42 EST

High14.45	Low13.62	Vol653.00K
Open13.71	D1 Closing13.71	Amplitude6.05%
Mkt Cap1.40B	Tradable Cap660.37M	Total Shares97.19M
T/O9.24M	T/O Rate1.42%	Tradable Shares45.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":14.37,"timestamp":1732654800000,"preClose":13.71,"halted":0,"volume":653004,"hourTrading":{"tag":"盘后","latestPrice":14.75,"preClose":14.37,"latestTime":"16:42 EST","volume":7266,"amount":104412.797832,"timestamp":1732657350570},"delay":0,"floatShares":45954472,"shares":97185475,"eps":-0.508218,"marketStatus":"Post-Market Trading","change":0.66,"latestTime":"11-26 17:58:57 EST","open":13.71,"high":14.45,"low":13.62,"amount":9242277.747911999,"amplitude":0.06054,"askPrice":14.75,"askSize":125,"bidPrice":14.25,"bidSize":120,"shortable":3,"etf":0,"ttmEps":-0.508218,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732669200000},"marketStatusCode":4,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":13.71,"preHourTrading":{"tag":"盘前","latestPrice":13.71,"preClose":13.71,"latestTime":"09:27 EST","volume":524,"amount":7190.809555999999,"timestamp":1732631260051},"postHourTrading":{"tag":"盘后","latestPrice":14.75,"preClose":14.37,"latestTime":"16:42 EST","volume":7266,"amount":104412.797832,"timestamp":1732657350570},"volumeRatio":0.605183,"impliedVol":0.6643,"impliedVolPercentile":0.2095},"requestUrl":"/m/hq/s/SPRY/tweets","defaultTab":"tweets","newsList":[{"id":"2485128012","title":"ARS Pharmaceuticals: Demand Curve Is Key Unknown","url":"https://stock-news.laohu8.com/highlight/detail?id=2485128012","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485128012?lang=en_us&edition=fundamental","pubTime":"2024-11-21 00:55","pubTimestamp":1732121758,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals' Neffy, a first non-injectable epinephrine nasal spray, recently launched in the U.S. and Europe, helping to drive a 140% YTD stock increase.The company has a solid balance sheet w","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4739046-ars-pharmaceuticals-demand-curve-is-key-unknown","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483327760","title":"Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2483327760","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483327760?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:50","pubTimestamp":1731671422,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at ARS Pharmaceuticals, Inc.'s  future prospects. ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. With the latest financial year loss of US$54m and a trailing-twelve-month loss of US$49m, the US$1.4b market-cap company alleviated its loss by moving closer towards its target of breakeven. Many investors are wondering about the rate at which ARS Pharmaceuticals will turn a profit, with the big question being “when will the company breakeven?”In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.Working backwards from analyst estimates, it turns out that they expect the company to grow 57% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.Management Team: An experienced","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/loss-making-ars-pharmaceuticals-inc-115022646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","TQQQ","SPRY","IE00BGHQF748.EUR","BK4585","BK4139","NDAQ","SQQQ","IE00BKPKM429.USD","QLD","NQmain","LU2095319765.USD","BK4112","BK4588","PSQ","MNQmain","LU2210150020.SGD","QID",".IXIC","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2483063308","title":"BRIEF-Neurelis Enters $208 Million Agreement To Monetize Intravail Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063308","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063308?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:02","pubTimestamp":1731592960,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - ARS Pharmaceuticals Inc   :   * NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIESSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483805202","title":"Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2483805202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483805202?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592824,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUABPYMYH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483939849","title":"ARS Pharmaceuticals Inc :  Leerink Partners Raises Target Price to $26 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2483939849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483939849?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:58","pubTimestamp":1731571130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483384844","title":"ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483384844","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483384844?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:08","pubTimestamp":1731568081,"startTime":"0","endTime":"0","summary":"Net Product Revenue for NEPI: $0.6 million from one week of sales.Total Operating Expenses: $23.8 million in Q3 2024.SG&A Expenses: $19.3 million, expected to increase in Q4 2024.GAAP Net Loss: $19.1 million or $0.20 per share in Q3 2024.Cash, Cash Equivalents, and Short-term Investments: $204.6 million at the end of Q3 2024.Pro Forma Cash Position: $349.6 million including $145 million upfront payment from ALK.GuruFocus has detected 3 Warning Sign with SPRY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The company has launched NEPHI in the U.S., with strong support and enthusiasm from patients, caregivers, and the medical community.A strategic licensing agreement with AOK has been established, expanding NEPHI's reach to Europe, Canada, and other regions.ARS Pharmaceuticals Inc  has a strong cash position of approximately $350 million, supporting its launch efforts and global expansion.The company is actively engaging with key payer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-q3-070801605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":1},{"id":"2483288630","title":"ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483288630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483288630?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:17","pubTimestamp":1731507463,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings SummaryARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2483040220","title":"BRIEF-ARS Pharmaceuticals Reports Q3 2024 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483040220","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483040220?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:56","pubTimestamp":1731502613,"startTime":"0","endTime":"0","summary":"Nov 13  - ARS Pharmaceuticals Inc   :   * ARS PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES   * ARS PHARMACEUTICALS: PDUFA TARGET DATE SET FOR MARCH 6, 2025   * ARS PHARMACEUTICALS: CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $204.6 MILLION AS OF SEPTEMBER 30, 2024Source text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483884939","title":"ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483884939","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483884939?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:40","pubTimestamp":1731501604,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals, Inc.  came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.13, delivering a surprise of -8.33%.ARS Pharmaceuticals, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $2.07 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 8.50%. This compares to zero revenues a year ago.While ARS Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-reports-124004917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2483008128","title":"ARS Pharmaceuticals Q3 2024 GAAP EPS $(0.20) Misses $(0.14) Estimate, Sales $2.068M Beat $565.000K Estimate. Cash and Equivalents Of $349.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008128","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008128?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:32","pubTimestamp":1731497559,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.14) by 42.86 percent. This is a 25 percent decrease over losses of $(0.16) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41934221/ars-pharmaceuticals-q3-2024-gaap-eps-0-20-misses-0-14-estimate-sales-2-068m-beat-565-000k-estimate-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ARS Pharmaceuticals Q3 2024 GAAP EPS $(0.20) Misses $(0.14) Estimate, Sales $2.068M Beat $565.000K Estimate. Cash and Equivalents Of $349.6M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2483086850","title":"ARS Pharmaceuticals Q3 Operating Income USD -21.748 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483086850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483086850?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX69CC25:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483600893","title":"ARS Pharmaceuticals Q3 Revenue USD 568 Thousand VS. Ibes Estimate USD 575 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2483600893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483600893?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX69CC25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483008956","title":"ARS Pharmaceuticals: Pdufa Target Date Set for March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008956?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA6CJXCL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483008509","title":"ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008509?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA6CJXCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2483008157","title":"ARS Pharmaceuticals: Cash, Cash Equivalents and Short-Term Investments Were $204.6 Mln as of September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008157?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA6CJXCL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2483008267","title":"Press Release: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008267","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008267?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497400,"startTime":"0","endTime":"0","summary":"Commercial launch of neffy  underway in the United States. Supplemental NDA for neffy 1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025. Exclusive license agreement with ALK-Abelló to commercialize neffy in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties. Well-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three years. On August 9, 2024, the FDA approved neffy  2 mg for the treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children who weigh >=30 kg . neffy was first available for shipment on September 23, 2024, and in early October, the U.S. sales force started in the field and neffy became broadly available in retail pharmacies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","SPRY","BK4232","R","BK4139"],"gpt_icon":0},{"id":"2482635739","title":"ARS Pharmaceuticals Inc    expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482635739","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482635739?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:34","pubTimestamp":1731339269,"startTime":"0","endTime":"0","summary":"* ARS Pharmaceuticals Inc     is expected to show a rise in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024   * The San Diego California-based  compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ARS Pharmaceuticals Inc    expected to post a loss of 15 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2482731944","title":"ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2482731944","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482731944?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:54","pubTimestamp":1731336851,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/ars-pharmaceuticals-neffy-nasal-spray-alk-abello-pharmaceuticals/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2482261785","title":"ARS Pharmaceuticals Licenses Neffy Nasal Spray to ALK-Abello for Europe, Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2482261785","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482261785?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:52","pubTimestamp":1731329567,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Monday it has granted ALK-Abello exclusive rights to commercialize neffy nasal spray, its emergency treatment for Type I allergic reactions, in Europe, Canada, and other territories outside the US.Under the licensing agreement, ARS Pharmaceuticals said it will receive $145 million upfront and up to $320 million in milestone payments, along with royalties.ARS will manufacture and supply neffy to ALK-Abello and retain US rights while there are no changes to partnerships for neffy in Japan, China, Australia and New Zealand, ARS Pharmaceuticals added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4588","SPRY","BK4500","ALK","BK4585","BK4008"],"gpt_icon":0},{"id":"2482408785","title":"ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482408785","media":"Benzinga","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482408785?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:41","pubTimestamp":1731328899,"startTime":"0","endTime":"0","summary":"On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. .The agreement grants ALK exclusive global rights to theneffy adrenaline  nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.In August, the FDA approvedARS Pharmaceuticals’ Neffy  for the emergency treatment of allergic reactions , including those that are life-threatening , foradult and pediatric patients.Neffy is also approved in Europe. Submission for regulatory approval in Canada is planned for by the end of 2024.ARS Pharma is also developing its intranasal adrenaline  technology for acute flares in patients with chronic urticaria, with plans to begin a Phase 2b trial in 2025.The license agreement gives ALK exclusive rights for new indications in the licensed territories.ALK will initially focus on bringingNeffy to Europe and Canada, the world’s second and third-largest adrenaline autoinjector markets. In both markets, the product can be added to ALK’s exi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8k6dOAMEvDt7_PBLdOtQ9w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/389ac3d6254a811ad876f37cecec65bf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8k6dOAMEvDt7_PBLdOtQ9w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/389ac3d6254a811ad876f37cecec65bf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inks-licensing-pact-124139720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SPRY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":-0.0718},{"period":"3month","weight":-0.0179},{"period":"6month","weight":0.5544},{"period":"1year","weight":1.8803},{"period":"ytd","weight":1.5018}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.09589},{"month":2,"riseRate":0.75,"avgChangeRate":0.156334},{"month":3,"riseRate":0.25,"avgChangeRate":-0.081262},{"month":4,"riseRate":0,"avgChangeRate":-0.132409},{"month":5,"riseRate":0.75,"avgChangeRate":0.018154},{"month":6,"riseRate":0.5,"avgChangeRate":0.064481},{"month":7,"riseRate":0.75,"avgChangeRate":0.142893},{"month":8,"riseRate":0.5,"avgChangeRate":-0.015111},{"month":9,"riseRate":0.25,"avgChangeRate":-0.231382},{"month":10,"riseRate":0.5,"avgChangeRate":0.000594},{"month":11,"riseRate":0.25,"avgChangeRate":0.024732},{"month":12,"riseRate":0.666667,"avgChangeRate":0.151109}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction